ESSITY-B Stock Analysis: Essity (publ) | ST
Household & Personal Products | ST, Sweden | Market Cap: 187.288m SEK | 12M Return: 18.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 359M
EPS Trend: 53.5%
Qual. Beats: -1
Rev. Trend: -92.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Essity AB (publ) is a Swedish hygiene and health products company founded in 1849 and headquartered in Stockholm. It operates through three segments: Health & Medical (incontinence, wound care, compression therapy, and orthopedics), Consumer Goods (feminine care, baby care, tissues, and toilet paper), and Professional Hygiene (away-from-home washroom and cleaning solutions), with sales reaching customers across Europe, the Americas, and Asia.
Classified within the Consumer Staples sector under Personal Care Products, the company runs a brand-driven business model built on well-known names such as TENA, Libresse, Zewa, Tempo, and Tork. Its distribution spans retail and e-commerce for consumer items alongside B2B direct sales and distributor networks for medical and professional hygiene customers.
- TENA incontinence sales accelerate on aging global demographics
- Pulp and energy costs remain key margin swing factor
- Tork Professional Hygiene rebounds with out-of-home traffic recovery
- Private label competition pressures European Consumer Goods pricing
| Net Income: 12.1b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.24 > 1.0 |
| NWC/Revenue: 3.37% < 20% (prev 11.79%; Δ -8.42% < -1%) |
| CFO/TA 0.10 > 3% & CFO 17.9b > Net Income 12.1b |
| Net Debt (39.7b) to EBITDA (25.7b): 1.54 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.1m) vs 12m ago -1.65% < -2% |
| Gross Margin: 33.31% > 18% (prev 32.66%; Δ 0.65% > 0.5%) |
| Asset Turnover: 78.85% > 50% (prev 85.56%; Δ -6.71% > 0%) |
| Interest Coverage Ratio: 16.24 > 6 (EBIT TTM 18.5b / Interest Expense TTM 1.14b) |
| A: 0.03 (Total Current Assets 57.1b - Total Current Liabilities 52.5b) / Total Assets 182b |
| B: 0.45 (Retained Earnings 81.3b / Total Assets 182b) |
| C: 0.11 (EBIT TTM 18.5b / Avg Total Assets 174b) |
| D: 1.05 (Book Value of Equity 92.8b / Total Liabilities 88.4b) |
| Altman-Z'' = 3.44 = A |
| DSRI: 1.10 (Receivables 28.4b/26.9b, Revenue 138b/143b) |
| GMI: 0.98 (GM 32.66% / 33.31%) |
| AQI: 1.04 (AQ_t 0.39 / AQ_t-1 0.38) |
| SGI: 0.96 (Revenue 138b / 143b) |
| TATA: -0.03 (NI 12.1b - CFO 17.9b) / TA 182b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at SEK 280.00 with a total of 947,240 shares traded. Over the past week, the price has changed by -0.46%, over one month by +1.86%, over three months by +14.29% and over the past year by +18.62%.
Current recommended Stop Loss: 272.40 (which is 2.7% or 1.4 ATR below the current price).
Essity (publ) has no consensus analysts rating.
P/E Trailing = 15.575
P/E Forward = 15.1976
P/S = 1.3614
P/B = 2.019
P/EG = 3.6186
Revenue TTM = 138b SEK
EBIT TTM = 18.5b SEK
EBITDA TTM = 25.7b SEK
Long Term Debt = 27.7b SEK (from longTermDebt, last fiscal year)
Short Term Debt = 17.1b SEK (from shortTermDebt, last quarter)
Debt = 46.6b SEK (from shortLongTermDebtTotal, last quarter) + Leases 3.96b
Net Debt = 39.7b SEK (calculated: Debt 46.6b - CCE 6.87b)
Enterprise Value = 227b SEK (187b + Debt 46.6b - CCE 6.87b)
Interest Coverage Ratio = 16.24 (Ebit TTM 18.5b / Interest Expense TTM 1.14b)
EV/FCF = 20.89x (Enterprise Value 227b / FCF TTM 10.9b)
FCF Yield = 4.79% (FCF TTM 10.9b / Enterprise Value 227b)
FCF Margin = 7.90% (FCF TTM 10.9b / Revenue TTM 138b)
Net Margin = 8.81% (Net Income TTM 12.1b / Revenue TTM 138b)
Gross Margin = 33.31% ((Revenue TTM 138b - Cost of Revenue TTM 91.7b) / Revenue TTM)
Gross Margin QoQ = 32.65% (prev 33.48%)
Tobins Q-Ratio = 1.25 (Enterprise Value 227b / Total Assets 182b)
Interest Expense / Debt = 2.45% (Interest Expense 1.14b / Debt 46.6b)
Taxrate = 26.22% (4.33b / 16.5b)
NOPAT = 13.7b (EBIT 18.5b * (1 - 26.22%))
Current Ratio = 1.09 (Total Current Assets 57.1b / Total Current Liabilities 52.5b)
Debt / Equity = 0.50 (Debt 46.6b / totalStockholderEquity, last quarter 92.8b)
Debt / EBITDA = 1.54 (Net Debt 39.7b / EBITDA 25.7b)
Debt / FCF = 3.65 (Net Debt 39.7b / FCF TTM 10.9b)
Total Stockholder Equity = 87.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.94% (Net Income 12.1b / Total Assets 182b)
RoE = 13.86% (Net Income TTM 12.1b / Total Stockholder Equity 87.4b)
RoCE = 16.08% (EBIT 18.5b / Capital Employed (Equity 87.4b + L.T.Debt 27.7b))
RoIC = 9.81% (NOPAT 13.7b / Invested Capital 139b)
WACC = 4.60% (E(187b)/V(234b) * Re(5.29%) + D(46.6b)/V(234b) * Rd(2.45%) * (1-Tc(0.26)))
Discount Rate = 5.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.46 | Cagr: -1.42%
[DCF] Terminal Value 77.97% ; FCFF base≈9.70b ; Y1≈11.1b ; Y5≈16.4b
[DCF] Fair Price = 332.3 (EV 246b - Net Debt 39.7b = Equity 207b / Shares 621.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 53.46 | EPS CAGR: 2.15% | SUE: -0.88 | # QB: -1
Revenue Correlation: -92.51 | Revenue CAGR: -7.70% | SUE: 0.64 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.74 | Chg30d=-3.22% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=18.98 | Chg30d=-0.17% | Revisions=-8% | GrowthEPS=+2.8% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=20.68 | Chg30d=+0.72% | Revisions=+8% | GrowthEPS=+9.0% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +5% (up=10, down=9)